Dr. Rao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
909 Fulton St SE
Minneapolis, MN 55455Phone+1 612-672-7422
Education & Training
University of New Mexico School of MedicineFellowship, Hematology and Medical Oncology, 2017
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2011 - 2014
OtherClass of 2010
All India Institute of Medical SciencesClass of 2010
Certifications & Licensure
TX State Medical License 2021 - 2026
MN State Medical License 2016 - 2024
NM State Medical License 2014 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer Start of enrollment: 2018 Nov 06
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Start of enrollment: 2018 Nov 26
Publications & Presentations
PubMed
- 59 citationsNK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In VivoDaniel A. Vallera, Soldano Ferrone, Behiye Kodal, Peter Hinderlie, Laura Bendzick
Cancers. 2020-09-18 - 1 citationsLenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNO...Chung-Han Lee, Amishi Yogesh Shah, Arpit Rao, Matthew H Taylor, Christopher Di Simone
European Urology. 2024-11-01 - 98 citationsLenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.Chung-Han Lee, Amishi Yogesh Shah, Drew W. Rasco, Arpit Rao, Matthew H. Taylor
The Lancet. Oncology. 2021-07-01
Press Mentions
Clovis Oncology Highlights Rubraca® (Rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021April 10th, 2021- Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual MeetingFebruary 11th, 2021
- Prostate Cancer Care Rebounding After COVID-19 DisruptionSeptember 1st, 2020
- Join now to see all
Other Languages
- Hindi, Gujarati, Spanish, Punjabi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
